GRAND MEDICAL (EUROPE)
0766.800.440 · rovalta.com · 27/09/2026
ACTIVE
GRAND MEDICAL (EUROPE)
Financial year 2025 · Closed on 31/12/2025
Net result-236 k €+10,2 %over 1 year
Gross margin-79,8 k €+20,0 %over 1 year
Equity-1,4 M €-19,8 %over 1 year
Workforce0,4 ETP-50,0 %over 1 year
Overview
Identity
Source · BCE/KBOGRAND MEDICAL (EUROPE) is a Private limited company incorporated in 2021. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Niel. It employs on average 0,4 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0766.800.440
- Incorporation
- 16/04/2021
- Legal form
- Private limited company
- Registered office
- Galileilaan 15
2845 Niel · FlandreSee on map - Contributed capital
- 20 000,00 €
- Latest accounts
- 31/12/2025
- Average workforce
- 0,4 ETP
Activities (NACE)
72101Research and experimental development on natural sciences and engineering· main72109Research and experimental development on natural sciences and engineering72110Research and experimental development on biotechnology72190Other research and experimental development on natural sciences and engineering21100Manufacture of basic pharmaceutical products21100Manufacture of basic pharmaceutical products+2
Joint committees (3)
- 207
- 2070
- 207,00
Signals
Healthy social debts
Financials
Source · NBB, 5 filingsTrend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -79,8 k € | +20.0% | -99,7 k € | +71.7% | -352,5 k € | -4.9% | -336,1 k € | -476% | -58,3 k € |
| EBITDA | -134,7 k € | +19.4% | -167,1 k € | +60.5% | -423,3 k € | -7.9% | -392,3 k € | -411% | -76,9 k € |
| Operating result | -134,7 k € | +20.1% | -168,5 k € | +60.4% | -425 k € | -7.9% | -394 k € | -410% | -77,2 k € |
| Net result | -236 k € | +10.2% | -262,8 k € | +43.9% | -468,7 k € | -15.7% | -405,2 k € | -420% | -77,9 k € |
| Balance sheet | |||||||||
| Equity | -1,4 M € | -19.8% | -1,2 M € | -28.2% | -931,8 k € | -101% | -463,1 k € | -700% | -57,9 k € |
| Total assets | 135,3 k € | -0.6% | 136,1 k € | +50.7% | 90,3 k € | -35.5% | 140 k € | +273% | 37,5 k € |
| Cash | 35,1 k € | -33.4% | 52,8 k € | +152% | 20,9 k € | -71.3% | 73,1 k € | +266% | 20 k € |
| Debts | 1,6 M € | +18.5% | 1,3 M € | +29.3% | 1 M € | +69.5% | 603,1 k € | +532% | 95,5 k € |
| Other | |||||||||
| Workforce | 0,4 ETP | -50.0% | 0,8 ETP | 0.0% | 0,8 ETP | 0.0% | 0,8 ETP | +167% | 0,3 ETP |
Board of directors
Source · NBB, accounts to 31/12/20253 active · 1 ended
Active mandates
Li Lei
ActiveTang Weikun
ActiveZhou Chao
ActiveEnded mandates
Lin Shi
EndedOther companies at this address
Galileilaan 15 2845 Niel| Company | CBE no. |
|---|---|
4VISO● Active | 1027.105.086 |
ADM● Active | 0463.498.167 |
BMCDENIS● Active | 0834.200.394 |
BRIGHTSPEC● Active | 0846.102.393 |
CAST4ALL● Active | 0469.659.053 |
CIRCLAIR● Active | 1017.358.665 |
CosProf Studio● Active | 1011.646.553 |
| 0692.724.114 | |
FiriX Therapeutics● Active | 1024.780.848 |
Hemplab Institute● Active | 0649.743.810 |
KARDECO● Active | 0427.600.348 |
| 0732.572.407 | |
MOBILAR● Active | 0779.489.327 |
NSX● Active | 0840.966.838 |
ORYX GROUP● Bankrupt | 0835.298.771 |
ORYX IT SERVICES● Bankrupt | 0835.842.565 |
OXYPOINT● Bankrupt | 0832.604.943 |
SIMMOCON● Active | 0786.692.269 |
Sodecon● Active | 0678.753.243 |
UBIS● Active | 0546.545.708 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 16/04/2021 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 9 months |
| Filing date | 08/09/2026 | 25/09/2025 | 01/10/2024 | 20/07/2023 | 29/07/2022 |
| General meeting | 17/08/2026 | 18/08/2025 | 23/08/2024 | 31/05/2023 | 23/06/2022 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 5 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 17/08/2026 | 08/09/2026 | Dutch | |
| Abridged model | 31/12/2024 | 18/08/2025 | 25/09/2025 | Dutch | |
| Abridged model | 31/12/2023 | 23/08/2024 | 01/10/2024 | Dutch | |
| Abridged model | 31/12/2022 | 31/05/2023 | 20/07/2023 | Dutch | |
| Abridged model | 31/12/2021 | 23/06/2022 | 29/07/2022 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20253 active · 1 ended
Active mandates
Li Lei
ActiveTang Weikun
ActiveZhou Chao
ActiveEnded mandates
Lin Shi
EndedOwnership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-236 k €↑
- 2024Annual accounts 2024-262,8 k €↑
- 2023Annual accounts 2023-468,7 k €↓
- 2022Annual accounts 2022-405,2 k €↓
- 2021Annual accounts 2021-77,9 k €
- 16/04/2021IncorporationPrivate limited company